logo
Plus   Neg
Share
Email

Pfizer Closes JV With GlaxoSmithKline, Forms GSK Consumer Healthcare

Pfizer Inc. (PFE) announced the closing of its joint venture with GlaxoSmithKline plc (GSK,GSK.L) to combine their respective consumer healthcare businesses.

The combined business, which will operate globally as GSK Consumer Healthcare, is now the world's largest over-the-counter or OTC business in Pain Relief, Respiratory and Vitamins, Minerals and Supplements, and Therapeutic Oral Health.

Under the deal terms, Pfizer owns a 32% equity stake in the joint venture and GSK owns 68%. The new JV will be led by CEO Brian McNamara.

As part of the agreement, Pfizer has appointed three out of the nine members of the joint venture's board.

Pfizer expects the transaction would deliver $650 million in peak cost synergies and to be slightly accretive on a full-year basis in each of the first three years following the closing.

GSK intends to separate the joint venture as an independent company through a demerger of its equity interest to its shareholders. The company plans to list the joint venture on the UK equity market.

GSK will have the sole right to decide whether and when to initiate a separation and listing for a period of five years following the closing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has unveiled Instagram Reels as its answer to the popular Chinese-owned video app TikTok. The social media giant said in a blog post that Instagram Reels is a new way to create short, entertaining videos on Facebook's photo-sharing app Instagram. Facebook reportedly shut down its TikTok clone Lasso in July, ahead of the launch of Instagram Reels. WD-40 Company recalled about 130,000 units of X-14 Mildew Stain Remover for potential risk of skin irritation, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said pressure can build up inside the bottle and cause it to fall over and leak, posing a risk of skin irritation. Biopharmaceutical company Bristol-Myers Squibb Co. on Thursday reported a loss for the second quarter, compared to a profit last year, hurt primarily by hefty amortization expenses. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. Looking ahead, the company raised its adjusted earnings and revenue outlook for the full-year 2020.
Follow RTT